The global In vivo CRO market size was valued at USD 3.07 billion in 2018 and is expected to expand at a CAGR of 8.5% over the forecast period. Increasing frequency of outsourcing R&D activities by the major pharmaceutical companies to focus on their core competencies is the major growth driver. Additionally, economic efficiency offered for outsourcing over conducting an in-house study is anticipated to increase the demand.
Contract Research Organization (CRO) services benefit sponsors/manufacturers to focus completely on the production capacity and augmenting their in-house processes. Also, the availability of extensive services from drug discovery to post-marketing surveillance has made it easy for small-scale and mid-size biotechnological and pharmaceutical companies by providing them the option to outsource what they think is beyond their core expertise.
As there is a patent cliff, many molecules are expiring, which is expected to drive the biosimilar industry. This, in turn, is expected to increase the number of R&D activities undertaken by the companies to commercialize the generic molecule. The race to launch the molecule in a feasible timeline and cost will propel the need for CRO service providers.
Toxicology and pharmacokinetic studies are the most commonly outsourced activities of preclinical studies by tier 1 pharma and biotechnology companies. The major reasons for these outsourcing activities have been highlighted to be the time and cost efficiency provided by the providers of such services. Over the forecast period, these activities are expected to rise due to rising focus and R&D budget allocation for the development of new products by the pharmaceutical companies.
Based on product type, the In vivo CRO market is bifurcated into rodent based and non-rodent based In vivo CRO testing. The rodent based In vivo CRO testing held a lucrative market share in 2018. Better correlation with the human system and abundant availability of genetically modified species drive the market growth. Among rodent based testing, mice is the most widely used animal and is poised for the fastest growth over the forecast period. This is owing to the small, inexpensive, and easy to handle organisms with shorter life span and faster reproduction rate.
On the basis of GLP type, the market is segregated non-GLP and GLP toxicology. GLP-based toxicology held the leading market share in 2018. In line with the regulatory bodies, contract research outsourcing firms mostly comply with the GLP guidelines to expedite the documentation process of the Investigational New Drug (IND) and carry on to clinical studies. The segment is also anticipated to witness the fastest CAGR over the forecast period owing to the increasing adoption of GLP compliance by emerging CROs and laboratories across the globe.
Based on indication type, the market is fragmented intoautoimmune/inflammatory conditions, pain management, oncology, CNS conditions, diabetes, obesity, and others. In 2018, majority of work was being done in the field of oncology, which contributes to about 28.08% of market share, owing to the increasing incidence of cancer cases and focus of pharmaceutical players on introducing new drug treatments with fewer side-effects.
Pain management is anticipated to form the most lucrative segment over the forecast period owing to the increasing incidence of chronic conditions that lead to severe pain.Moreover, rising investigation for analgesic molecules and new Non-Steroidal Anti-Inflammatory Drug (NSAID) is projected to be the vital impact rendering growth driver. Pain management has been further segregated into chronic and acute pain wherein acute pain segment is anticipated to witness the fastest growth.
North America led the global market in 2018 with major contribution from U.S. Increased funding has boosted the research activities in the region.U.S. has the highest per capita healthcare spending and availability of funding and grants from government organizations such as the National Institute of Health (NIH) to foster research activities.Increasing R&D activities and need to reduce overall trial expenditure are expected to drive the need for CROs in North America.
Asia Pacific is the fastest growing market owing to many developed countries investing in this regions along with various amendments made by the regulatory market to change the clinical trials evaluation standards to match the global platform. In October 2014, the Australian CRO Novotech started a new office in China, its ninth office in Asia. Novotech, as a company, has expanded in many developing nations owing to the request by its U.S. and EU clients.
In addition, in February 2014, Charles River Laboratories declared China as a country with disproportionate growth and expressed interest in merging with potential regions in the country. Moreover, with the availability of qualified labor and other resources, Asia Pacific would be the key destination for In vivo CRO projects over the forecast period.
Some of the key market players include Pharmaceutical Product Development, LLC (PPD); Quintiles; ICON Plc; Parexel International; American Preclinical Services, LLC; Covance Inc.;Theorem Clinical research; WuXi AppTec, Inc.; inVentiv Health; Evotec (US), Inc.; and Charles River Laboratories. The market players are undertaking various strategies such as collaborations and mergers and acquisitions.
Base year for estimation
Actual estimates/Historical data
2015 - 2017
2019 - 2026
Revenue in USD Million and CAGR from 2019 to 2026
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
U.S., Canada, U.K., Germany, France, Italy, Spain, China, Japan, India, Australia, South Korea, Mexico, Brazil, Argentina, South Africa, Saudi Arabia, UAE
Revenue forecast, competitive landscape, growth factors and trends
15% free customization scope (equivalent to 5 analyst working days)
If you need specific information, which is not currently within the scope of the report, we will provide it to you as a part of customization
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends and opportunities in each of the sub-segments from 2015 to 2026. For the purpose of this study, Grand View Research has segmented the global In vivo CRO market report on the basis of product type, GLP type, indication, and region:
Type Outlook (Revenue, USD Million, 2015- 2026)
GLP Type Outlook (Revenue, USD Million, 2015 - 2026)
Indication Outlook (Revenue, USD Million, 2015 - 2026)
Autoimmune/ Inflammatory Conditions
Irritable Bowel Syndrome
Patient Derived Xenograft
Traumatic Brain Injury
Regional Outlook (Revenue, USD Million, 2015 - 2026)
Middle East & Africa
This report has a service guarantee. We stand by our report quality.
We are in compliance with GDPR & CCPA norms. All interactions are confidential.
Design an exclusive study to serve your research needs.
Get your queries resolved from an industry expert.
"The quality of research they have done for us has been excellent..."
With Covid-19 infections rising globally, the apprehension regarding a shortage of essential life-saving devices and other essential medical supplies in order to prevent the spread of this pandemic and provide optimum care to the infected also widens. In addition, till a pharmacological treatment is developed, ventilators act as a vital treatment preference for the COVID-19 patients, who may require critical care. Moreover, there is an urgent need for a rapid acceleration in the manufacturing process for a wide range of test-kits (antibody tests, self-administered, and others). The report will account for Covid19 as a key market contributor.